Enumeration of circulating tumor cells (CTCs) demonstrated strong correlation with disease progression, treatment response, and minimal residual disease (MRD) across cancer patients.
Quantitative monitoring of CTC levels provided insights into tumor burden and dynamic changes in disease status during treatment.
Fluctuations in CTC burden over time reflected therapeutic efficacy, enabling clinicians to evaluate treatment response in real time.
Persistent or rising CTC counts may indicate residual disease activity or early signs of disease progression.
CTC-based monitoring offers a non-invasive liquid biopsy approach for longitudinal cancer surveillance.
Regular assessment of circulating tumor cells may support early detection of relapse or treatment resistance before radiologic progression becomes evident.
Integration of CTC enumeration into clinical monitoring strategies may enhance personalized treatment planning and therapy adjustments.
Overall, CTC-based disease monitoring represents a valuable biomarker strategy for precision oncology, real-time treatment evaluation, and long-term cancer management.
Read Abstract